NX Development Corp. (NXDC) Names Salvatore DeSena, M.D., as Chief Executive Officer
March 02, 2022 10:54 ET
|
NX Development Corp.
Lexington, KY, March 02, 2022 (GLOBE NEWSWIRE) -- NX Development Corp. (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced that Salvatore DeSena, M.D., has...
T.J. Stalvey Joins NX Development Corp. (NXDC) as Vice President of Clinical Development and Medical Affairs
April 15, 2021 10:00 ET
|
NX Development Corp.
Lexington, KY, April 15, 2021 (GLOBE NEWSWIRE) -- NX Development Corp. (NXDC), a life-sciences company wholly owned by photonamic GmbH & Co. KG., today announced that Tracy Jerome “T.J.” ...
NX Development Corp. (NXDC) Receives FDA Orphan-Drug Designation for Gleolan® (aminolevulinic acid HCl) in Meningioma
January 12, 2021 10:10 ET
|
NX Development Corp.
Lexington, KY, Jan. 12, 2021 (GLOBE NEWSWIRE) -- NX Development Corp. (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced FDA orphan-drug designation for...
NX Development Corp. (NXDC) Launches Gleolan (aminolevulinic acid HCl) Meningioma Phase III Clinical Trial (NXDC-MEN-301)
November 17, 2020 14:12 ET
|
NX Development Corp.
Lexington, KY, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NX Development Corp (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced the enrollment of the first...
NX Development Corp. (NXDC) Launches FDA-Approved Gleolan™ (aminolevulinic acid HCl) for Enhanced Visualization of High-Grade Gliomas (including Glioblastomas)
October 03, 2018 14:50 ET
|
NX Development Corp.
Lexington, KY, Oct. 03, 2018 (GLOBE NEWSWIRE) -- NX Development Corp. (NXDC), a life sciences company, today announced the U.S. commercial launch of its flagship product Gleolan™ (aminolevulinic...